The NR3C1 (nuclear receptor subfamily 3 group C member 1) gene encodes the glucocorticoid receptor (GR), a nuclear receptor very important for sustaining physiological homeostasis, and inhibition of NR3C1 may improve the sensitivity of most cancers cells to straightforward chemotherapy, significantly in ovarian most cancers. Notably, the FDA has permitted a medical proof‑of‑idea research of the NR3C1 inhibitor relacorilant plus nab‑paclitaxel in most cancers. Past oncology, NR3C1 inhibitors reveals additionally therapeutic promise in nervous, cardiovascular, immune and metabolism methods, boasting a large indication space.
Until date, the evolution of NR3C1 inhibitors has efficiently addressed the selectivity and off-target toxicity points that plagued the primary technology, but the sector continues to battle with the benefit-risk steadiness in non-cancer indications. There’s an pressing want for next-generation inhibitors to beat the persistent limitations of present benchmarks, significantly the excessive threat of drug-drug interactions.
Insilico Drugs (03696.HK), a clinical-stage, generative AI-driven drug discovery firm, in the present day introduced the nomination of ISM6200 as a potent, probably best-in-class preclinical candidate (PCC) focusing on NR3C1, for the remedy of ovarian most cancers, Hypercortisolism (Cushing’s Syndrome), and different issues associated to extra cortisol together with weight problems. The method was empowered by Chemistry42, the generative chemistry engine affiliated to Insilico’s Pharma.AI, in addition to the specialised functions throughout the molecule discovery and optimization cycle.
In platinum-resistant ovarian most cancers, sufferers face an general survival of solely about one 12 months, so the sector is looking for brand new therapies. ISM6200 was particularly engineered with excellent properties, together with decrease DDI dangers, which permit broader mixture choices. Extra importantly, the molecule can ship robust efficacy at a a lot decrease projected human dose, providing a safer and simpler remedy path for sufferers in want.”
Dr. Feng Ren, Co-CEO and Chief Scientific Officer of Insilico Drugs
As proven in preclinical research, ISM6200 is a small molecule candidate with low DDI threat and better in vivo efficacy throughout a number of animal fashions. In a preclinical CDX (cell line-derived xenograft) mannequin, ISM6200 demonstrated vital and dose-dependent enhancement of anti-tumor efficacy when mixed with paclitaxel. Additionally, a positive ADME and pharmacokinetic profile help robust systemic publicity and a low predicted efficacious dose in people, and its stable developability profile marked by good stability lays the muse as a therapeutically efficient agent.
“We initially recognized NR3C1 using twin goal analysis associated to ageing – it scored in a number of age-related illnesses. We began engaged on a portfolio of small molecule medicine focusing on NR3C1 to assist unlock the complete potential of this goal whereas avoiding the recognized on-target liabilities. The nomination of ISM6200 highlights the transformative energy of generative AI in addressing complicated medicinal chemistry challenges whereas lowering conventional dangers akin to metabolic instability and off-target toxicity,” stated Alex Zhavoronkov, PhD, Founder and Co-CEO of Insilico Drugs. “I’m particularly inspired by multi-purpose candidates like this one, as it’s indicated in methods throughout the physique, even exceeding our expectation of focusing on each ageing and sure illnesses. By utilizing AI, we will determine high-quality molecules with broad potential, in document time, and we’re advancing extra pipelines with AI-driven effectivity.”
Notably, the nomination of ISM6200 marks one other step ahead in Insilico’s cardiometabolic portfolio, which was first launched at BIO-Europe 2025, with the NR3C1 program as a key asset holding potential to reverse cortisol-driven metabolic dysfunction and improve semaglutide-mediated weight reduction.
Within the DIO mouse mannequin, ISM6200 demonstrated weight reduction impact, primarily lowering fats whereas higher retaining muscle mass. After 28 days of administration, in contrast with the management group, ISM6200 monotherapy achieved vital weight reduction, with a relative weight discount of 8.8% from the baseline. When ISM6200 was mixed with Semaglutide, the load loss impact was additional enhanced, reaching 23.8% inside the identical administration interval, whereas the DIO management group gained 2.4% in weight. The above knowledge supplied robust help for subsequent medical improvement.
In a rat mannequin of Cushing’s syndrome, ISM6200 considerably alleviated insulin resistance and decreased blood stress. Following 6-day remedy, insulin resistance ranges have been diminished by 68%, and blood stress approached the degrees noticed in wholesome management teams. Moreover, within the therapeutic glaucoma mannequin, after 3 days of dexamethasone injection adopted by 3 days of ISM6200 remedy, measurements revealed a big lower in intraocular stress (IOP) in mice, offering clues for subsequent medical improvement.
ISM6200 is the twenty ninth Preclinical/Developmental Candidate (PCC/DC) Nomination by Insilico. Since 2021, 12 PCCs obtained IND clearance, 3 entered Section II, amongst which 1 Section IIa trial is accomplished, with 10+ enterprise improvement offers marking superior high quality of Insilico PCC and excessive requirements.
